Loading…
Opus Genetics, Inc. is projected to rise to $3.75 by 2027, a +1% move from its current price of $3.71. IRD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.57 | $3.71 | $3.86 | +0.01% |
| Aug 4 | $3.51 | $3.71 | $3.92 | +0.01% |
| Aug 5 | $3.47 | $3.71 | $3.97 | +0.02% |
| Aug 6 | $3.43 | $3.71 | $4.01 | +0.03% |
| Aug 7 | $3.40 | $3.71 | $4.05 | +0.03% |
| Aug 8 | $3.37 | $3.71 | $4.09 | +0.04% |
| Aug 9 | $3.34 | $3.71 | $4.12 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.34 | $3.71 | $4.12 | +0.05% |
| Week 2 | $3.21 | $3.71 | $4.30 | +0.10% |
| Week 3 | $3.10 | $3.72 | $4.45 | +0.14% |
| Week 4 | $3.02 | $3.72 | $4.58 | +0.19% |
| Week 5 | $2.95 | $3.72 | $4.69 | +0.24% |
| Week 6 | $2.88 | $3.72 | $4.80 | +0.29% |
| Week 7 | $2.83 | $3.72 | $4.90 | +0.33% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Opus Genetics, Inc. is a healthcare company focused on developing gene therapies to restore vision and prevent blindness in inherited retinal diseases (IRDs). It is a clinical-stage biopharmaceutical company pursuing therapies such as OPGx-LCA5 for early-onset retinal degeneration and OPGx-BEST1 for BEST1-associated retinal disease.
The company also develops multiple pre-clinical IRD programs, including OPGx-RHO, OPGx-RDH12, OPGx-MERTK, OPGx-NMNAT1, and OPGx-CNGB1, and it has ophthalmic therapies in development such as Phentolamine Ophthalmic Solution for reversal of mydriasis and APX3330 for diabetic retinopathy. Opus Genetics was formerly Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc.
in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
These details position Opus Genetics within the Healthcare sector as a clinical-stage company advancing gene therapies and ophthalmic treatments for IRDs and related disorders. The description highlights its focus on restoring vision and preventing blindness through a pipeline that spans both gene therapies and small-molecule approaches.
Opus Genetics, Inc. (IRD) is currently priced at $3.84 with a market cap of $317.05M and a rank of 3233. These figures place the stock among smaller-cap healthcare names with a focus on specialized ocular therapies.
The multi-year forecast portrays upside across the horizon, with the average price projected to rise from $3.84 in 2026 to $7.18 by 2030 and $31.53 by 2050, implying material long-term upside. The forecasted ROI values progress from 0 in 2026 to 87 in 2030 and reach 721.2 by 2050, signaling strong potential over extended horizons despite near-term volatility.
Overall, the outlook combines near-term neutral-to-bullish positioning with substantial longer-term upside, driven by the expansion of its IRD programs and other ophthalmic therapies.
A major floor 37.7% below — a decisive break under it would weaken the trend.
The nearest floor, 21.3% below — buyers have tended to step in here.
The nearest ceiling, 14.0% above — a clean break opens room to run.
A major ceiling 55.0% above — clearing it would confirm fresh momentum.
Key IRD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IRD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.56 | Buy | $3.57 | Buy |
| MA 10 | $3.29 | Buy | $3.47 | Buy |
| MA 20 | $3.53 | Buy | $3.54 | Buy |
| MA 50 | $3.87 | Sell | $3.84 | Sell |
| MA 100 | $4.43 | Sell | $3.92 | Sell |
| MA 200 | $3.46 | Buy | $3.49 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.64 | Neutral |
| Stoch RSI (14) | 88.25 | Sell |
| CCI (20) | 36.76 | Neutral |
| Williams %R (14) | -14.13 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 6.61 | Buy |
| Bollinger %B (20,2) | 0.62 | Neutral |
| Stochastic %K (14) | 85.87 | Sell |
| TRIX (15) | -0.80 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 64.47 | Neutral |
| Momentum (10) | 0.44 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 3.80 | Sell |
| ADX (14) | 22.95 | Buy |
| ATR (14) | 0.13 | Info |
The near-term technical picture shows a bullish stance, with RSI14 at 60 indicating continued positive momentum.
The 50-day simple moving average is $3.88 and the 200-day simple moving average is $3.45, suggesting the price is trading near its mid-range relative to longer-term trends. Support is at $2.92 and resistance at $4.23, framing a trading range around the current level. The 30-day price range spans from $2.95 to $4.99, highlighting the stock’s modest volatility over the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.93 | $3.71 | $4.86 | 0% | Neutral | |
| $2.87 | $3.75 | $5.25 | +1% | Neutral | |
| $3.05 | $4.16 | $6.12 | +12% | Neutral | |
| $4.19 | $5.92 | $9.06 | +60% | Bullish | |
| $4.48 | $6.54 | $10.35 | +76% | Bullish | |
| $4.44 | $6.67 | $10.85 | +80% | Bullish | |
| $4.66 | $7.20 | $12.01 | +94% | Bullish | |
| $4.29 | $6.81 | $11.61 | +83% | Bullish | |
| $4.81 | $7.81 | $13.60 | +111% | Bullish | |
| $5.88 | $9.78 | $17.37 | +164% | Bullish | |
| $6.76 | $12.59 | $24.20 | +239% | Bullish | |
| $12.08 | $26.84 | $57.73 | +623% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.93 | $3.71 | $4.67 | +0.00% |
| September 2026 | $3.13 | $3.75 | $4.65 | +1.07% |
| October 2026 | $3.08 | $3.73 | $4.70 | -0.44% |
| November 2026 | $3.16 | $3.86 | $4.92 | +3.33% |
| December 2026 | $3.07 | $3.77 | $4.86 | -2.26% |
Click any year to see its month-by-month IRD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IRD price prediction for 2026 points to an average of $3.71 (low $1.93, high $4.86) — a potential gain of 0% on today's $3.71. Price action looks broadly range-bound.
In 2027, IRD is projected to trade between $2.87 and $5.25, averaging $3.75 — a potential gain of +1% from today's $3.71. That is up +1% on the projected 2026 average. A consolidation phase looks the most probable path here.
Opus Genetics, Inc.'s 2028 outlook centres on $4.16, within a $3.05 to $6.12 range. That is up +11% on the projected 2027 average. That marks a +12% change versus current levels. Price action looks broadly range-bound.
By 2029, IRD could reach as high as $9.06, with a base case around $5.92 and support toward $4.19 — roughly +60% from $3.71. Buyers look set to stay in control over this stretch.
Expect IRD to range from $4.48 to $10.35 through 2030. The $6.54 average target implies a +76% move from current prices. That is up +11% on the projected 2029 average. Momentum favours further upside here.
The IRD price prediction for 2031 points to an average of $6.67 (low $4.44, high $10.85) — a potential gain of +80% on today's $3.71. Buyers look set to stay in control over this stretch.
In 2032, IRD is projected to trade between $4.66 and $12.01, averaging $7.20 — a potential gain of +94% from today's $3.71. That is up +8% on the projected 2031 average. Momentum favours further upside here.
Opus Genetics, Inc.'s 2033 outlook centres on $6.81, within a $4.29 to $11.61 range. That is -5% versus the projected 2032 average. That marks a +83% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, IRD could reach as high as $13.60, with a base case around $7.81 and support toward $4.81 — roughly +111% from $3.71. Momentum favours further upside here.
Expect IRD to range from $5.88 to $17.37 through 2035. The $9.78 average target implies a +164% move from current prices. That is up +25% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The IRD price prediction for 2040 points to an average of $12.59 (low $6.76, high $24.20) — a potential gain of +239% on today's $3.71. Momentum favours further upside here.
In 2050, IRD is projected to trade between $12.08 and $57.73, averaging $26.84 — a potential gain of +623% from today's $3.71. That is up +113% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IRD today (≈ 269.541779 IRD) could be worth
$7,233.38
+$6,233.38 (+623%) by 2050 · US Dollar
Based on the average projected IRD price of $26.84 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IRDwould be worth at today's price.
$1,000 invested in IRD on Jul 31, 2025 (≈ 900.900889 IRD) would be worth
$3,342.34
+$2,342.34 (+234.2%) today · 3.34× · US Dollar
Based on a IRD entry price of $1.11 vs. today's $3.71.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.08 | $1,204.55 | +20.5% |
| 1 month ago | $4.18 | $887.56 | -11.2% |
| 3 months ago | $5.14 | $721.79 | -27.8% |
| 6 months ago | $2.32 | $1,599.14 | +59.9% |
| 1 year ago | $1.11 | $3,342.34 | +234.2% |
| All time (5.0y) ago | $4.67 | $794.43 | -20.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IRD forecast.
Our base-case forecast reaches $7.40 around 2034.
Implied market cap at $7.40: $610.99M
The multi-year forecast depicts a clear path higher, with 2026 at an average price of $3.84 and 2027 at $3.96, then accelerating to $4.51 in 2028 and $6.48 in 2029. By 2030 the average is projected to $7.18, with an ROI of 87 and bullish sentiment, followed by continued gains through 2031 ($7.36, ROI 91.7) and 2032 ($7.98, ROI 107.8).
The forecast continues to push higher into 2033 ($7.62, ROI 98.5) and 2034 ($8.89, ROI 131.4), with 2035 at $11.23 and ROI of 192.5. By 2040, the average price is $14.74 (ROI 283.9) and by 2050, the average price is $31.53 with ROI of 721.2, reflecting substantial long-run upside despite inherent uncertainty and volatility. The annualized volatility is 80%, underscoring the high risk around these projections.
Tap a question to reveal the answer.
The forecasted average price is $7.18 with an ROI of 87 and bullish sentiment.
The long-run forecast shows strong upside with an average price of $31.53 in 2050 and ROI of 721.2, but near-term outlook varies (2026 avg $3.84, ROI 0) and volatility is high (annualized 80%). The estimates are not guaranteed.
In 2040 the forecasted average price is $14.74 with an ROI of 283.9 and bullish sentiment.
Current price is $3.84 and market cap is $317.05M.
The 30-day range is $2.95 to $4.99, with support at $2.92 and resistance at $4.23.
Opus Genetics, Inc. Community Discussion
0Share your Opus Genetics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.